Transcriptome and Regulatory Network Analyses of CD19-CAR-T Immunotherapy for B-ALL

Chimeric antigen receptor (CAR) T cell therapy has exhibited dramatic anti-tumor efficacy in clinical trials. In this study, we reported the transcriptome profiles of bone marrow cells in four B cell acute lymphoblastic leukemia (B-ALL) patients before and after CD19-specific CAR-T therapy. CD19-CAR-T therapy remarkably reduced the number of leukemia cells, and three patients achieved bone marrow remission (minimal residual disease negative). The efficacy of CD19-CAR-T therapy on B-ALL was positively correlated with the abundance of CAR and immune cell subpopulations, e.g., CD8+ T cells and natural killer (NK) cells, in the bone marrow. Additionally, CD19-CAR-T therapy mainly influenced the expression of genes linked to cell cycle and immune response pathways, including the NK cell mediated cytotoxicity and NOD-like receptor signaling pathways. The regulatory network analyses revealed that microRNAs (e.g., miR-148a-3p and miR-375), acting as oncogenes or tumor suppressors, could regulate the crosstalk between the genes encoding transcription factors (TFs; e.g., JUN and FOS) and histones (e.g., HIST1H4A and HIST2H4A) involved in CD19-CAR-T therapy. Furthermore, many long non-coding RNAs showed a high degree of co-expression with TFs or histones (e.g., FOS and HIST1H4B) and were associated with immune processes. These transcriptome analyses provided important clues for further understanding the gene expression and related mechanisms underlying the efficacy of CAR-T immunotherapy.

[1]  E. Mejstrikova,et al.  Leukemia surfaceome analysis reveals new disease-associated features. , 2013, Blood.

[2]  D. Longo,et al.  A Milestone for CAR T Cells. , 2017, The New England journal of medicine.

[3]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[4]  Bernd Hauck,et al.  Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.

[5]  Zhiqiang Wu,et al.  New development in CAR-T cell therapy , 2017, Journal of Hematology & Oncology.

[6]  Ç. Avcı,et al.  Evaluation of the miRNA profiling and effectiveness of the propolis on B-cell acute lymphoblastic leukemia cell line. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[7]  S Balachandran,et al.  JUN is a key transcriptional regulator of the unfolded protein response in acute myeloid leukemia , 2017, Leukemia.

[8]  H. Abken,et al.  Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells , 2013, Front. Immunol..

[9]  E. Ségal-Bendirdjian,et al.  cFos Mediates cAMP-Dependent Generation of ROS and Rescue of Maturation Program in Retinoid-Resistant Acute Promyelocytic Leukemia Cell Line NB4-LR1 , 2012, PloS one.

[10]  Nataly Cruz-Rodriguez,et al.  High expression of ID family and IGJ genes signature as predictor of low induction treatment response and worst survival in adult Hispanic patients with B-acute lymphoblastic leukemia , 2016, Journal of Experimental & Clinical Cancer Research.

[11]  Jeong Eon Lee,et al.  Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer , 2017, Nature Communications.

[12]  M. Relling,et al.  Genome-wide approach to identify risk factors for therapy-related myeloid leukemia , 2006, Leukemia.

[13]  Hui Hu,et al.  AnimalTFDB 3.0: a comprehensive resource for annotation and prediction of animal transcription factors , 2018, Nucleic Acids Res..

[14]  Qian Zhang,et al.  GSA: Genome Sequence Archive* , 2017, Genom. Proteom. Bioinform..

[15]  Aaron Smith,et al.  Chimeric antigen receptor (CAR) T cell therapy for malignant cancers: Summary and perspective , 2016 .

[16]  A. Fraser,et al.  Nuclear receptor binding protein 1 regulates intestinal progenitor cell homeostasis and tumour formation , 2012, The EMBO journal.

[17]  E Soeda,et al.  Molecular dynamics of MHC genesis unraveled by sequence analysis of the 1,796,938-bp HLA class I region. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Wei Liu,et al.  miR-146b-5p within BCR-ABL1-Positive Microvesicles Promotes Leukemic Transformation of Hematopoietic Cells. , 2016, Cancer research.

[19]  E. Kimby,et al.  TCL1A expression delineates biological and clinical variability in B-cell lymphoma , 2009, Modern Pathology.

[20]  Seth M Steinberg,et al.  T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial , 2015, The Lancet.

[21]  Ying Lin,et al.  Transcription factor and miRNA co-regulatory network reveals shared and specific regulators in the development of B cell and T cell , 2015, Scientific Reports.

[22]  S. Albelda,et al.  Chimeric antigen receptor T-cell therapy for solid tumors , 2016, Molecular therapy oncolytics.

[23]  Mel Greaves,et al.  Acute lymphoblastic leukaemia , 2013, The Lancet.

[24]  Yang Feng,et al.  CD22-CAR T Cells Induce Remissions in CD19-CAR Naïve and Resistant B-ALL , 2017, Nature Medicine.

[25]  H. Beier,et al.  Novel upstream and intragenic control elements for the RNA polymerase III-dependent transcription of human 7SL RNA genes. , 2004, Biochimie.

[26]  K. Tobinai,et al.  Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges , 2019, Drugs in context.

[27]  L. Ouafik,et al.  OTX015 (MK‐8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models , 2016, International journal of cancer.

[28]  Michele Markstein,et al.  Modulation of let-7 miRNAs controls the differentiation of effector CD8 T cells , 2017, eLife.

[29]  M. T. Dorak,et al.  An extensive analysis of the hereditary hemochromatosis gene HFE and neighboring histone genes: associations with childhood leukemia , 2010, Annals of Hematology.

[30]  K. Curran,et al.  Toxicity and management in CAR T-cell therapy , 2016, Molecular therapy oncolytics.

[31]  Michel Sadelain,et al.  Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. , 2011, Blood.

[32]  J. Kline,et al.  Mechanisms of Immune Tolerance in Leukemia and Lymphoma. , 2017, Trends in immunology.

[33]  Qiong Zhang,et al.  GSCALite: a web server for gene set cancer analysis , 2018, Bioinform..

[34]  B. Levine,et al.  Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist. , 2016, The oncologist.

[35]  W. Lim,et al.  The Principles of Engineering Immune Cells to Treat Cancer , 2017, Cell.

[36]  Takashi Akasaka,et al.  Five members of the CEBP transcription factor family are targeted by recurrent IGH translocations in B-cell precursor acute lymphoblastic leukemia (BCP-ALL). , 2007, Blood.

[37]  Qing He,et al.  Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia , 2014, Science Translational Medicine.

[38]  John R. Mascola,et al.  Gene transfer in humans using a conditionally replicating lentiviral vector , 2006, Proceedings of the National Academy of Sciences.

[39]  A. Krishnan,et al.  Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor–Redirected T Cells Against Multiple Myeloma , 2017, Clinical Cancer Research.